Evidence map›Paper›PMID 39158690›Full record

ArticleEuropean journal of clinical pharmacology2024

Evaluation of SLC6A2 and CYP2D6 polymorphisms' effects on atomoxetine treatment in attention deficit and hyperactivity disorder.

Ismail Hasan Kole, Pınar Vural, Beste Yurdacan, Adem Alemdar, Caner Mutlu

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of clinical pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ismail Hasan KoleDepartment of Child and Adolescent Psychiatry, Faculty of Medicine, Bursa Uludag University, Bursa, Türkiye. hasankole@uludag.edu.tr.
Pınar VuralDepartment of Psychology, Faculty of Humanities and Social Sciences, Fatih Sultan Mehmet Vakif University, Istanbul, Türkiye.
Beste YurdacanDepartment of Medical Biology, Faculty of Medicine, Bursa Uludag University, 16059, Bursa, Türkiye.
Adem AlemdarDepartment of Medical Biology, Faculty of Medicine, Bursa Uludag University, 16059, Bursa, Türkiye.
Caner MutluDepartment of Child and Adolescent Psychiatry, Faculty of Medicine, Bursa Uludag University, Bursa, Türkiye. canermutlu@uludag.edu.tr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere is insufficient replicated data to establish a relationship between the polymorphisms of SLC6A2 and CYP2D6 and the treatment responses of atomoxetine (ATX) in ADHD. We focused on evaluating the effect of top-line single nucleotide polymorphisms (SNPs) in SLC6A2 and CYP2D6 on the ATX treatment response in attention deficit and hyperactivity disorder (ADHD).

methodsOf 160 patient records, 34 patients who met the inclusion criteria were evaluated to determine the relationship between genotypes of ten SNPs (six of SLC6A2 and four of CYP2D6) and ATX treatment response. Additionally, the connection between SNPs of CYP2D6 and the severity of side effects associated with ATX was analyzed in 37 patients, including the 34 study patients, and three patients discontinued because of ATX-dependent side effects.

resultsAll six polymorphisms we studied in SLC6A2 were associated with the treatment response of ATX. Clinical improvement in oppositional defiant disorder symptoms of patients with ADHD was only observed in carriers of the homozygous "C" allele of rs3785143 (p

conclusionsThe findings of this study suggest that genotypes of polymorphisms within the SLC6A2 and CYP2D6 may play an influential role in treatment response or the severity of side effects associated with ATX in ADHD patients.

Indexed as

Adrenergic Uptake InhibitorsAtomoxetine HydrochlorideAttention Deficit Disorder with HyperactivityCytochrome P-450 CYP2D6GenotypePolymorphism, Single NucleotideAdolescentChildFemaleHumansMaleNorepinephrine Plasma Membrane Transport ProteinsTreatment OutcomeAdrenergic Uptake InhibitorsAtomoxetine HydrochlorideCytochrome P-450 CYP2D6Norepinephrine Plasma Membrane Transport ProteinsSLC6A2 protein, humanAtomoxetineAttention deficit and hyperactivity disorderCYP2D6Genetic polymorphismSLC6A2

Identifiers

PMID39158690

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.